C O Onyeji
Overview
Explore the profile of C O Onyeji including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
167
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Igbinoba S, Akanmu M, Onyeji C, Soyinka J, Owolabi A, Nathaniel T, et al.
J Clin Pharm Ther
. 2015 Jul;
40(5):545-549.
PMID: 26177778
What Is Known And Objectives: Some studies, howbeit with conflicting reports, have suggested that consumption of honey has a potential to modulate drug metabolizing enzymes which may result in a...
2.
Onyeji C, Omoruyi S, Oladimeji F
Pharmazie
. 2007 Dec;
62(11):858-63.
PMID: 18065103
Halofantrine (HF) is a poorly water-soluble antimalarial drug with low bioavailability. Complex formation of HF.HCl and 2-hydroxypropyl-beta-cyclodextrin (HP-beta-CD) in aqueous solution and in solid state as well as the possibility...
3.
Onyeji C, Ogunbona F
Eur J Pharm Sci
. 2001 Apr;
13(2):195-201.
PMID: 11297904
The significance of a pharmacokinetics basis in chloroquine (CQ)-induced pruritus was investigated by determining the disposition of the drug in two groups of volunteers; pruritus positive and pruritus negative. Single...
4.
Nicolau D, Onyeji C, Banevicius M, Li J, Nightingale C
Pharmacotherapy
. 2001 Mar;
21(3):275-80.
PMID: 11253851
Study Objective: To examine whether the antienterococcal efficacy of a regimen of gentamicin plus vancomycin combined with granulocyte colony-stimulating factor (G-CSF) is enhanced by concurrent therapy with interferon-gamma (IFN-gamma). Setting:...
5.
Onyeji C, Nicolau D, Nightingale C, Bow L
J Antimicrob Chemother
. 2000 Sep;
46(3):429-36.
PMID: 10980170
It has been demonstrated previously that, in non-neutropenic animals, interferon-gamma markedly enhances the efficacies of gentamicin and vancomycin against Enterococcus faecalis resistant to these antibiotics. The aim of our study...
6.
Nicolau D, Onyeji C, Zhong M, Tessier P, Banevicius M, Nightingale C
Antimicrob Agents Chemother
. 2000 Apr;
44(5):1291-5.
PMID: 10770764
Cefprozil, an oral semisynthetic cephalosporin, is commonly utilized in the treatment of respiratory-tract infections in children. While this agent has provided acceptable clinical success over a number of years, this...
7.
Onyeji C, Adebayo A, Babalola C
Eur J Pharm Sci
. 2000 Jan;
9(2):131-6.
PMID: 10620725
The need to develop chloroquine suppository formulations that yield optimal bioavailability of the drug has been emphasized. This study demonstrates the effects of incorporation of known absorption-enhancing agents (nonionic surfactants...
8.
Onyeji C, Bui K, Nicolau D, Nightingale C, Bow L, Quintiliani R
Int J Antimicrob Agents
. 1999 Sep;
12(4):301-9.
PMID: 10493606
Increasing antibiotic resistance and the development of multidrug-resistance in the enterococci has complicated the treatment of serious enterococcal infections. It has been demonstrated in vitro that interferon-gamma (IFN-gamma) significantly augments...
9.
Onyeji C, Bui K, Owens Jr R, Nicolau D, Quintiliani R, Nightingale C
Int J Antimicrob Agents
. 1999 Jul;
12(2):107-14.
PMID: 10418754
The in vivo efficacies of levofloxacin and ciprofloxacin were compared against three clinical isolates of Streptococcus pneumoniae, using a mouse protection model. Two strains (SP 22 and SP 28) were...
10.
Tessier P, Nicolau D, Onyeji C, Nightingale C
Chemotherapy
. 1999 Jul;
45(4):284-95.
PMID: 10394012
Cefepime, a fourth-generation cephalosporin, is currently one of the primary agents used in combination with an aminoglycoside when treating Pseudomonas aeruginosa infections. The bactericidal activity of cefepime administered as intermittent...